Sendegobresib

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** An orally bioavailable heterobifunctional protein degrader of bromodomain-containing protein 9 (BRD9; sarcoma antigen NY-SAR-29; rhabdomyosarcoma antigen MU-RMS-40.8), with potential antineoplastic activity. Sendegobresib is comprised of an E3 ligase-binding moiety and a BRD9-binding moiety. Upon oral administration, sendegobresib targets and binds to BRD9 with its BRD9-binding moiety. Upon BRD9 binding, the E3 ligase-binding moiety binds to cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex, which directs proteins for destruction, resulting in the proteasome-mediated degradation of BRD9. This leads to an inhibition of the growth of tumor cells that rely on BRD9 for survival. BRD9, a component of one form of the Brg/Brahma-Associated Factor (BAF) complex, is needed for the survival of certain cancer cells due to mutations.

**Synonyms:** - BRD9 Degrader CFT8634 - BRD9 Protein Degrader CFT8634 - BRD9-targeting Protein Degrader CFT8634 - BiDAC Degrader CFT8634 - Bifunctional Degradation Activating Compound CFT8634 - CFT 8634 - CFT-8634 - CFT8634 - SENDEGOBRESIB